HomeAI · summaries
Storia in 20 fonti
Moderna und Merck: Krebsimpfstoff Intismeran besteht Phase 3 – Aktien steigen massiv
Meilenstein für die mRNA-Onkologie: Der personalisierte Krebsimpfstoff Intismeran von Moderna und Merck besteht die entscheidende Phase-3-Studie. Die Moderna-Aktie verdoppelt sich, auch BioNTech profitiert.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…
- ·
en.mercopress.com
A personalized mRNA therapy passes a phase 3 melanoma trial for the first time
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…
